Physician profile
Catherine Remus
NPI 1023099694
$2,399.90
in general payments reported to CMS, 2019-2025
15 companies · $542 in 2025
The $542 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $140 · 2021: $348 · 2022: $354 · 2023: $307 · 2024: $36.91 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $865.75 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Pfizer INC. | $279.53 | 2019-2025 | |
| Tris Pharma INC | $260.35 | 2019-2025 | Onyda Xr |
| Glaxosmithkline, LLC. | $255.51 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $193.35 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $151.13 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $124.09 | 2025 | |
| Ironshore Pharmaceuticals INC. | $117.10 | 2019-2020 | |
| Alk-Abello, INC | $32.96 | 2025 | Neffy |
| Aytu Biopharma, INC. | $30.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.73 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.29 | 2025 | Alvesco |
| Cranial Technologies, INC | $17.05 | 2025 | Doc Band |
| Merck Sharp & Dohme LLC | $15.53 | 2025 | Vaxneuvance, Rotateq, Enflonsia |
| Arbor Pharmaceuticals, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Remus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.